Foresee Pharmaceuticals Co., Ltd. (TPEx: 6576), a Taiwan-based biopharmaceutical company developing long-acting injectable medicines, announced on October 12, 2026, that China’s National Medical Products Administration had approved CAMCEVI 42 mg, its ready-to-use six-month leuprolide mesylate depot formulation, for treating adults with advanced prostate cancer. The approval, communicated through its Chinese licensing partner Changchun GeneScience Pharmaceutical Co., Ltd., establishes a regulatory pathway for commercial sales in China under an exclusive licensing agreement signed in November 2020. GeneScience will lead Chinese commercialisation, although neither company disclosed a confirmed launch date, product price or sales forecast.
The decision represents an important geographical expansion for a medicine already approved in the United States, European Union and several other markets. CAMCEVI is designed to maintain testosterone suppression through a single subcutaneous injection administered approximately every six months, while its prefilled, ready-to-use presentation eliminates the reconstitution or mixing steps required by certain other injectable hormone therapies. Its underlying active ingredient, leuprolide, is well established in prostate cancer treatment, meaning the product’s principal differentiation lies in formulation, administration and commercial execution rather than a new mechanism of anticancer action.
The approval also advances a licensing relationship that gives Foresee exposure to Chinese sales without requiring it to establish a wholly owned local commercial organisation. Under the original arrangement, Foresee secured an $8 million upfront payment and eligibility for up to $123.85 million in regulatory, technology-transfer and commercial milestones, together with a share of territory revenue. The October announcement did not identify a specific milestone payment triggered by the approval, leaving the near-term financial contribution uncertain even as the product moves closer to launch.
Why does China’s CAMCEVI 42 mg approval matter for advanced prostate cancer treatment?
The approval gives Changchun GeneScience Pharmaceutical an authorised six-month leuprolide formulation for the Chinese advanced prostate cancer market. Prostate cancer treatment frequently involves androgen deprivation therapy, particularly for patients with advanced or metastatic disease whose tumours depend on androgen signalling. Leuprolide is a gonadotropin-releasing hormone agonist that reduces testosterone production after an initial period of hormonal stimulation.
CAMCEVI’s principal commercial feature is its combination of sustained drug release and a ready-to-use prefilled syringe. Certain established leuprolide depot products require preparation or reconstitution before administration, adding steps to the injection procedure. Foresee’s formulation is designed to simplify that process while maintaining drug exposure over a six-month dosing interval.
The company’s regulatory filing identifies October 8, 2026, as the date of the underlying approval event, although the formal public announcement was issued on October 12. The decision follows earlier authorisations for CAMCEVI in the United States and Europe, where the product has already accumulated clinical and commercial experience. However, the Chinese approval applies specifically to adults with advanced prostate cancer and should not be interpreted as authorisation for every disease being investigated with Foresee’s leuprolide formulations.
China represents a potentially substantial market because of its large population and increasing prostate cancer burden. Foresee’s Taiwanese exchange disclosure cited approximately 164,000 new prostate cancer cases annually in mainland China, based on the market information used in its regulatory announcement. That figure describes newly diagnosed prostate cancer across disease stages rather than the number of patients eligible for CAMCEVI, making it unsuitable as a direct estimate of the product’s commercial market.
How does CAMCEVI maintain testosterone suppression for six months without repeated injections?
CAMCEVI was developed using Foresee’s proprietary Stabilized Injectable Formulation technology, which is intended to deliver medicines through long-acting injectable preparations. The product contains leuprolide mesylate formulated as a sustained-release injectable emulsion, with a 42 mg leuprolide dose administered subcutaneously once every six months. Its formulation allows the active ingredient to be released over an extended period instead of requiring frequent administration.
Leuprolide acts on gonadotropin-releasing hormone receptors in the pituitary gland. Initial stimulation temporarily increases reproductive hormone signalling and can produce a rise in testosterone, but sustained receptor stimulation eventually suppresses luteinising hormone and follicle-stimulating hormone secretion. This reduces testicular testosterone production to levels associated with medical castration.
Testosterone suppression remains an established therapeutic approach in advanced prostate cancer because androgen signalling can support tumour growth and progression. However, reducing testosterone is not the same as directly eliminating cancer cells, and patients may require additional systemic therapies depending on disease characteristics and progression. CAMCEVI’s principal pharmacological objective is sustained hormonal suppression rather than introducing a novel anticancer mechanism.
The ready-to-use presentation provides another distinction. The product is supplied in a prefilled syringe, avoiding the need to manually combine drug components before administration. This could simplify preparation procedures in oncology and urology settings, although improvements in preparation time, medication-error rates or overall clinical efficiency would require supporting comparative evidence.
The dosing interval could also reduce the number of scheduled hormone-treatment injections compared with shorter-acting formulations. Nevertheless, six-month administration is not unique to CAMCEVI, and other long-acting androgen deprivation therapies are available. Its competitive position will depend on the complete combination of preparation requirements, clinical performance, availability and price.
What do CAMCEVI’s Phase III results establish about long-term testosterone suppression?
CAMCEVI’s United States registration programme included an open-label, single-arm international study, FP01C-13-001, involving 137 patients with prostate cancer. Participants received a 42 mg subcutaneous injection at the beginning of treatment and a second injection at week 24. The study evaluated whether the formulation could achieve and maintain testosterone suppression over approximately 48 weeks.
The principal efficacy measure was the proportion of patients achieving and maintaining serum testosterone concentrations at or below 50 ng/dL, a commonly used threshold for medical castration. According to the United States prescribing information, 98.5% of patients achieved testosterone suppression to this level by week four, within the specified assessment window. The estimated proportion maintaining suppression from week four through week 48 was 97.0%, with a 95% confidence interval of 92.2% to 98.9%.
These findings support the ability of the formulation to provide sustained hormonal suppression across two six-month dosing periods. They are relevant to the Chinese approval because reliable testosterone control is an important pharmacological requirement for long-acting gonadotropin-releasing hormone agonists. However, the October 2026 announcement did not provide a new numerical efficacy analysis from a separate Chinese pivotal study.
A more stringent testosterone threshold of 20 ng/dL was also assessed in the original clinical programme. Approximately 69.3% of patients achieved concentrations at or below this level on day 28. This provides additional information about the depth of hormonal suppression, although it should not be confused with the study’s primary efficacy definition.
Prostate-specific antigen concentrations declined during treatment, with average reductions of approximately 51% at four weeks and 83% after three months. These observations are consistent with pharmacological activity, but the United States label cautions against interpreting the speed of prostate-specific antigen decline as evidence of clinical benefit. The study was not designed to establish an improvement in overall survival compared with alternative androgen deprivation therapies.
The original trial also had limitations relevant to interpreting its findings across different populations. It was not a randomised head-to-head comparison, and approximately 90% of enrolled participants were White, while 4% were Asian. The regulatory evidence supports sustained testosterone suppression, but it does not independently establish that CAMCEVI is superior to existing hormone-treatment formulations used in China.
What safety risks remain relevant despite CAMCEVI’s established regulatory approvals?
The clinical safety profile of CAMCEVI reflects both the effects of androgen deprivation and the risks associated with leuprolide therapy. Its United States prescribing information warns that gonadotropin-releasing hormone agonists can produce a temporary increase in testosterone during the first weeks of treatment. This initial hormonal surge can worsen symptoms in certain patients, including bone pain, urinary obstruction and complications associated with spinal cord compression.
The approved United States label also includes warnings concerning hyperglycemia, diabetes, cardiovascular events and QT interval prolongation. These are important considerations because many patients requiring long-term androgen deprivation therapy are older and may have additional cardiovascular or metabolic conditions. The product’s six-month dosing interval does not eliminate the need for appropriate clinical monitoring.
In the 137-patient registration study, hot flushes were reported in 50% of participants, hypertension in 15% and injection-site reactions in 11%. Serious adverse reactions were recorded in 15% of patients, while fatal adverse reactions were reported in 2%. These findings describe safety observations from the registration population and should not be interpreted as establishing comparative risks against other available prostate cancer medicines.
The United States prescribing information was also updated to address severe cutaneous adverse reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. These uncommon but potentially life-threatening reactions are relevant to the broader benefit-risk assessment of leuprolide-containing therapies. Their inclusion in the label reinforces the need to distinguish convenient administration from an inherently safer medicine.
The precise prescribing requirements in China will depend on the locally approved product information. Although CAMCEVI uses the same established active ingredient, regulatory labels may differ between jurisdictions in their indications, warnings, presentation and administration instructions. The October announcement does not provide the complete Chinese prescribing information, preventing a detailed comparison with the United States label.
How does the Changchun GeneScience licensing agreement translate China’s approval into commercial opportunity?
Foresee Pharmaceuticals and Changchun GeneScience Pharmaceutical entered their exclusive Chinese licensing arrangement in November 2020. GeneScience is a subsidiary of Changchun High-Tech Industry (Group) Co., Ltd., a Shenzhen-listed Chinese company with established pharmaceutical operations. The agreement covers the development and commercialisation of CAMCEVI formulations within China, giving Foresee a regional partner with local regulatory and commercial capabilities.
The original agreement included an upfront payment of $8 million to Foresee. It also provided for additional regulatory, technology-transfer and commercial milestone payments totalling up to $123.85 million, alongside a share of revenue generated from the licensed products. GeneScience assumed responsibility for development, registration and commercialisation costs within the territory.
These terms establish several possible revenue streams, but they have different conditions and accounting implications. The upfront payment was associated with the original licensing arrangement, while the additional milestones depend on specified contractual events. Revenue sharing is linked to commercial activity and therefore depends on actual sales and the applicable agreement terms.
China’s approval is a meaningful regulatory milestone within that arrangement, but Foresee has not disclosed whether it triggered a specific payment or how much additional revenue, if any, will be recognised immediately. It would therefore be inappropriate to describe the full $123.85 million as newly secured income. The amount represents the original maximum contingent milestone opportunity, not confirmed proceeds from this approval alone.
The same distinction applies to future product revenue. Foresee may benefit from GeneScience’s commercial sales through the agreed economic structure, but the companies have not disclosed the precise revenue-sharing percentage or a forecast of initial sales. The approval establishes the ability to pursue commercialisation under the new authorisation, while actual financial contributions will depend on subsequent execution.
Can CAMCEVI compete in China’s established leuprolide and prostate cancer hormone therapy market?
China already has an established market for androgen deprivation therapies, including formulations containing leuprolide and other gonadotropin-releasing hormone agonists. Products using goserelin, triptorelin and related hormonal mechanisms also compete for clinical use, while other androgen deprivation approaches offer different administration and pharmacological characteristics. CAMCEVI is therefore entering an established treatment category rather than introducing hormonal suppression as an entirely new therapeutic concept.
Foresee’s Taiwanese regulatory disclosure cited a Chinese leuprolide acetate market with annual sales exceeding RMB 5 billion during recent years. It also referenced third-party forecasts suggesting that the Chinese injectable leuprolide acetate microsphere market could reach approximately RMB 6.8 billion in 2026 and exceed RMB 8.7 billion by 2030. These are company-cited category estimates, not verified market-share forecasts or direct projections of CAMCEVI sales.
The distinction between an established medicine category and an obtainable product market is important. Patients may already be receiving effective depot formulations, and physicians will evaluate the clinical and practical reasons for changing treatment. Competitive pricing, reimbursement, hospital access and confidence in consistent testosterone suppression may influence prescribing decisions as much as the convenience of a ready-to-use presentation.
GeneScience’s existing commercial infrastructure could help the product reach relevant oncology and urology prescribers. However, the company has not announced a confirmed nationwide rollout schedule, reimbursement listing or hospital procurement agreements for CAMCEVI. Regulatory approval removes an essential market-entry barrier but does not establish immediate access across China’s healthcare system.
The product’s storage and supply requirements will also influence commercial execution. The United States version requires refrigerated storage, and long-acting injectable medicines generally depend on appropriately controlled distribution and product handling. The final Chinese supply arrangements will need to satisfy the locally approved product specifications, while availability will depend on GeneScience’s manufacturing and distribution execution.
Why do the breast cancer and central precocious puberty programmes matter to the CAMCEVI franchise?
The Chinese approval concerns advanced prostate cancer, but Foresee’s GeneScience partnership extends beyond this indication. The companies have also pursued leuprolide development for premenopausal breast cancer and central precocious puberty, reflecting the broader role of gonadotropin-releasing hormone suppression across different endocrine conditions. These programmes create potential opportunities for additional approvals, although each requires its own supporting evidence and regulatory decision.
In May 2026, GeneScience submitted a supplemental New Drug Application in China for a leuprolide mesylate injectable emulsion intended for premenopausal breast cancer. The National Medical Products Administration accepted that application for substantive review. The October announcement confirms that the application remains a separate regulatory programme and does not describe breast cancer as an approved CAMCEVI indication in China.
The treatment rationale differs from that in prostate cancer. Suppression of ovarian function can form part of endocrine treatment strategies for selected premenopausal patients with hormone-sensitive breast cancer. However, clinical use depends on the exact indication, disease characteristics and supporting evidence, meaning prostate cancer approval cannot be extrapolated to breast cancer treatment.
Foresee is separately developing its FP-001 six-month formulation for central precocious puberty. The Phase III CASPPIAN trial reached its primary endpoint in December 2025, supporting further regulatory development. Foresee has indicated plans for a United States submission during the second half of 2026 and is preparing commercial infrastructure for potential future launches in the United States and Taiwan.
These programmes demonstrate how the same long-acting formulation technology can be developed for different hormone-dependent conditions. Nevertheless, the company must establish appropriate dosing, efficacy and safety for each population, particularly when moving from adult cancer treatment into paediatric endocrinology. No approval for central precocious puberty should be inferred from the Chinese prostate cancer decision.
How does China’s approval affect Foresee Pharmaceuticals’ financial performance and investor sentiment?
Foresee Pharmaceuticals trades on the Taipei Exchange under ticker 6576, giving investors direct exposure to its clinical development and licensing strategy. Unlike companies that commercialise medicines principally through their own international sales organisations, Foresee relies substantially on regional partnerships and the associated licensing, development and product-related revenue. Its financial performance can therefore be affected by the timing of milestone recognition and partner activity.
The company reported second-quarter 2026 sales of approximately NT$181.65 million, compared with NT$111.65 million a year earlier. Its quarterly net loss narrowed to NT$123.78 million from NT$329.41 million. For the first six months, revenue reached approximately NT$261.96 million, while the company reported a net profit of NT$283.14 million compared with a loss of NT$622.5 million in the corresponding 2025 period.
More recent monthly disclosures illustrate the variability of the revenue profile. Foresee reported approximately NT$325.24 million in cumulative consolidated revenue for the first nine months of 2026, down 14.2% from the same period of the previous year. September revenue was approximately NT$6.27 million, reinforcing the distinction between periodic licensing-related receipts and a consistently growing base of recurring commercial sales.
The Chinese approval introduces another potential contributor to future product-related revenue, but the financial magnitude remains uncertain. Commercial demand, GeneScience’s pricing strategy, the timing of any milestones and the terms governing revenue sharing will determine how much economic value ultimately reaches Foresee. The regulatory milestone strengthens the franchise’s geographical reach without independently resolving the company’s broader revenue variability.
Foresee shares closed at NT$80.00 on October 12, 2026, increasing 2.3% from their previous trading-session close of NT$78.20. The stock had also traded below its 52-week high, indicating that the market was evaluating the company against a broader set of development and financial considerations. The session’s increase coincided with the company’s disclosure of the Chinese approval, although the movement cannot be attributed exclusively to that announcement.
From an investment perspective, CAMCEVI’s growing international approval footprint offers the possibility of broader licensing and commercial revenue. However, the value of the Chinese authorisation cannot be determined solely from historical category-market estimates or the original milestone agreement. Subsequent disclosures of launch progress, earned payments and recurring sales will provide a more reliable measure of financial impact.
How does the China approval strengthen Foresee’s long-acting injectable development strategy?
CAMCEVI is the most commercially advanced example of Foresee’s Stabilized Injectable Formulation platform. The company’s strategy involves developing sustained-release medicines that address limitations involving dosing frequency, product preparation or formulation performance. Successful international registration of CAMCEVI provides evidence that the platform can support commercially authorised drug products.
The company is also expanding its formulation work into central nervous system medicines. Programmes identified in its latest pipeline include FP-018, a long-acting cariprazine formulation, and FP-016, a long-acting vesicular monoamine transporter 2 inhibitor programme. Foresee has indicated that these candidates are expected to enter human clinical testing in late 2027, making them substantially earlier-stage assets than CAMCEVI.
Their development illustrates the potential breadth of the platform, but the achievement of regulatory approval for leuprolide does not establish that the technology will perform successfully with unrelated active ingredients. Different molecules present distinct solubility, stability, pharmacokinetic and manufacturing requirements. Each new formulation will require its own preclinical, clinical and regulatory evaluation.
Foresee has also adjusted its broader development strategy through external partnerships. In January 2026, the company announced an agreement licensing its matrix metalloproteinase-12 inhibitor programmes to Primevera Therapeutics, enabling it to concentrate additional resources on its long-acting injectable portfolio. The Chinese CAMCEVI approval supports that strategic emphasis by advancing an existing programme into another potential commercial market.
What milestones will determine whether CAMCEVI succeeds commercially in China?
The immediate milestone will be GeneScience’s confirmation of the Chinese commercial launch. Foresee chairman and chief executive Ben Chien indicated that the company expected its partner to introduce CAMCEVI in China and regarded the approval as an important contributor to the global franchise. However, the October 12 announcement does not identify the date of the first commercial shipment or establish that product sales have begun.
Subsequent developments involving pricing, reimbursement and hospital access will provide stronger evidence about the product’s competitive position. A six-month dosing interval and ready-to-use syringe may offer practical advantages for healthcare delivery, but prescribing decisions will continue to depend on reliable testosterone suppression, safety, product availability and overall treatment costs. GeneScience’s execution in these areas will largely determine the commercial contribution of the newly authorised product.
The financial follow-through will be equally important for Foresee. Confirmation of any regulatory milestone earned under the 2020 agreement, together with subsequent disclosures of product-related revenue, would clarify how approval translates into economic value. The potential $123.85 million milestone pool should remain separate from payments actually achieved and the revenue attributable to commercial sales.
The pending Chinese breast cancer application represents another measurable regulatory milestone, while the central precocious puberty programme offers a separate development opportunity. These potential indications could broaden the future commercial scope of the leuprolide platform, but the present approval remains limited to adults with advanced prostate cancer. Their outcomes will depend on independent regulatory assessments rather than the existing authorisation.
Foresee’s October 2026 announcement marks the conversion of a longstanding Chinese development partnership into an approved pharmaceutical opportunity. CAMCEVI has already demonstrated sustained testosterone suppression in its established registration programme, while the new authorisation gives GeneScience a ready-to-use six-month formulation for the Chinese market. The decisive commercial test will now shift from regulatory acceptance to launch execution, physician adoption and the extent to which sales and contractual milestones generate recurring value for Foresee Pharmaceuticals.
